Obesity - Identifying and Commercializing First-in-Class Innovation

www.MarketResearchReports.com
Category : Pharma & Healthcare
All logos and Images mentioned on this slide belong to their respective owners.

Introduction to Report
 Launch Date: October 1, 2015
 Number of Pages: 87
 Geography Coverage: Global
 Available Format: PDF
Price For Single User License: USD 6,995
Price For Site User License: USD 13,990
Price For Global User License: USD 20,985
Delivery Time: Within 24 Hours (During Working Days)

About the Report
Frontier Pharma: Obesity - Identifying and
Commercializing First-in-Class Innovation report provides
analysis of the obesity treatment pipeline, stratified by
stage of development, molecule type and molecular
target. It includes information on the current clinical and
commercial landscape, and the composition of the
obesity therapeutics market in terms of dominant
molecule types and targets, as well as highlighting current
unmet needs.
Obesity is a major growing health concern around the
world. In most markets, a person is considered obese if
their Body Mass Index (BMI) exceeds 30 kilograms per
square meter (kg/m2), calculated by dividing body mass
in kilograms by height in meters squared.

Key Highlights:
Anti-obesity pharmacotherapy can be used as an adjunct
lifestyle modification to improve weight loss in order to
significantly reduce obesity-associated health risks in
obese patients.
However, the use of currently available anti-obesity
drugs is largely limited by poor long-term safety and a
modest weight loss effect.
Despite substantial clinical and regulatory challenges,
the early-stage obesity pipeline remains robust,
containing a high level of first-in-class innovation that has
the potential to be translated into effective and safe
weight loss treatments.

Key Highlights Continues…
The company’s latest report states that despite the
current market’s clinical and regulatory challenges, the
obesity pipeline is robust and contains a high level of
diversity in both molecule types and molecular targets,
with 39% of the pipeline products with disclosed
molecular targets classified as first-in-class.
Senior Analyst, says that while most pipeline products
target gut hormone receptors, the remainder target a
wide range of processes thought to be dysregulated in
obesity, such as angiogenesis, insulin signaling,
inflammation, fat absorption, lipid synthesis, and
metabolism.
The high level of innovation and diversity in molecular
target in development is encouraging, with a number of
these not only showing close alignment to the disease
pathophysiology but also addressing multiple
mechanisms underpinning the development of obesity.

Reasons to Buy:
Understand the current clinical and commercial
landscape by considering disease pathogenesis, diagnosis,
prognosis, and the available treatment options and their
limitations in terms of safety and efficacy.
Visualize the composition of the obesity market to
highlight the current unmet needs in order to gain a
competitive understanding of the key opportunities.
Analyze the obesity pipeline and stratify by stage of
development, molecule type, and molecular target; the
diversity of molecular targets in the pipeline is extremely
encouraging as obesity is characterized by the complex
interplay between central and peripheral mechanisms.

Reasons to Buy Continues…
Assess the therapeutic potential of first-in-class targets
using a proprietary matrix that assesses and ranks first-in-
class products according to clinical potential.
Target the most promising and innovative obesity
products for early-stage investment by analyzing trends in
licensing and co-development deals and accessing a
curated list of first-in-class therapies potentially open to
deal-making opportunities.

Report Coverage:
1. Executive Summary
2. The Case for Innovation
3. Clinical and Commercial Landscape
4. Assessment of Pipeline Product Innovation
5. Signaling Pathways, Genetics and Innovation
Alignment
6. First-in-Class Target Evaluation
7. Deals and Strategic Consolidations
8. Appendix
For more details regarding Report coverage see the last slide
All logos and Images mentioned on this slide belong to their respective owners.

Custom Research:
 Are you an industry professional, entrepreneur,
venture capitalist, investors and organization, then let
us know your specific research requirements. Our goal
is to cater to your requirements be it for a custom
market research project, syndicated research report on
a specific market or industry sector, newsletter creation,
case study development or anything else related to
marketing research.
For Any Customization Related query Visit IdeaCenter @
http://www.marketresearchreports.com/idea-center
For regular industry updates subscribe to our newsletter
at:
http://www.marketresearchreports.com/subscribe-to-
newsletter

How To Buy This Report?
Visit following URL to see Table of Content and
purchase this publication:
http://mrr.cm/oXY
About Market Research Reports, Inc.
Market Research Reports provides a customized set
of reports from reputed Publishers, built on the
intelligence available within organizations and
leverages on our motto of “Intelligence Redefined”.
Contact : Amitava Sen
Email : info@marketresearchreports.com
Phone: +1 302-703-7787 (USA) +91-8762746600 (India)

Obesity - Identifying and Commercializing First-in-Class Innovation

Recommended

Recommended

More Related Content

Viewers also liked

Viewers also liked (7)

More from Market Research Reports, Inc.

More from Market Research Reports, Inc. (20)

Recently uploaded

Recently uploaded (20)

Obesity - Identifying and Commercializing First-in-Class Innovation